Cooper Companies posted 8% revenue growth and 26% non-GAAP EPS growth in Q2, with premium contact lenses and fertility driving the story. A strategic review at CooperSurgical adds a potential value catalyst, while debt and Asia Pacific weakness keep the risk profile moderate.
The investment thesis for The Cooper Companies (COO) is a moderate-risk Buy built on three facts: fiscal Q2 2026 revenue rose 8% to $1.08B, non-GAAP EPS rose 26% to $1.21, and management reaffirmed fiscal 2026 non-GAAP EPS guidance of $4.58 to $4.66. CooperVision continues to gain share in premium contact lenses, while CooperSurgical delivered 6% organic growth and is the subject of a strategic review that could expose value not reflected in the current stock price.
The case is not risk-free. The balance sheet carries roughly $2.5B of debt against $110.6M of fiscal 2025 cash, Asia Pacific remains a drag on CooperVision, and a $271.6M litigation charge pushed Q2 GAAP EPS to a loss of $0.40. At the referenced share price of $70.64, however, the forward P/E is 14.1x and the PEG ratio is 0.7. Those figures offer a better lens on the earnings recovery than the 58.6x trailing P/E, which is distorted by the recall-related charge and other items.
The medium-term opportunity rests on recurring demand, product upgrades, myopia management and operating leverage. The principal judgment call is whether Cooper can convert strong premium-lens and fertility execution into durable earnings growth while managing tariffs, foreign exchange and debt. The evidence currently supports measured accumulation rather than an aggressive position.
Founded in 1958 and headquartered in San Ramon, California, COO is a NASDAQ-listed healthcare company with approximately 15,000 employees. It operates through CooperVision and CooperSurgical and sells through distributors, group purchasing organizations, eye-care professionals, hospitals, clinics, retailers and authorized resellers.
CooperVision develops and markets spherical, toric, multifocal and myopia-management contact lenses. CooperSurgical supplies fertility products and services, genomics, medical devices, contraception and cryostorage. The company operates in more than 130 countries and states that its products affect more than 50 million lives annually, giving COO broad geographic reach and a large installed customer base.
Fiscal 2025 revenue was $4.09B. CooperVision generated $2.74B, or 67.0% of total revenue, while CooperSurgical generated $1.35B, or 33.0%. The mix makes COO primarily a recurring-consumables business. Contact lenses require repeat purchases, while fertility and women's-health products are often embedded in clinical workflows and replenishment cycles.
CooperVision generated Q2 revenue of $723.5M, up 8.0% reported and 4.0% organically. Toric and multifocal lenses produced $364.9M and grew 7.0% organically, while sphere and other products generated $358.6M and grew 1.0% organically. The mix favors higher-complexity prescriptions, where fitting expertise and product breadth matter more than simple unit volume.
Regional performance was uneven. The Americas generated $303.2M and grew 7.0%, while EMEA generated $289.7M and grew 6.0% organically. Asia Pacific generated $130.6M and declined 6.0%, reflecting weak demand in Japan and China plus the deliberate removal of legacy hydrogel products. Management expects Asia Pacific to return to roughly market growth in the fourth quarter and to grow in line with the market during 2027.
CooperSurgical generated Q2 revenue of $358.0M, up 8.0% reported and 6.0% organically. Fertility revenue reached $143.8M and grew 10.0% organically. Office and surgical products generated $214.2M and grew 4.0%, with medical devices up 6.0% and Paragard revenue flat. Fertility is currently the stronger growth engine, supported by genomics, capital equipment, consumables, new clinic wins and expansion inside existing accounts.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
MyDay is the flagship growth brand within CooperVision's daily silicone hydrogel portfolio. Daily silicone hydrogel lenses grew 8.0% in Q2, and management reported double-digit growth for MyDay driven by customer partnerships and premium products. The brand benefits from the industry's migration toward daily wear, a shift that supports recurring volume and premium mix.
MiSight is COO's most distinctive specialty product. Q2 MiSight revenue rose 24.0% to $32M. The lens has FDA approval for slowing myopia progression in children who begin treatment between ages 8 and 12, along with approvals in China and Japan. The Japanese launch is exceeding management's expectations, and the MyDay MiSight launch in Europe is receiving strong practitioner adoption.
Biofinity remains the key frequent-replacement franchise. It grew 5.0% organically in Q2, led by toric and multifocal lenses. Its extended ranges and made-to-order products offer more than six times the prescription options of all other monthly brands combined, according to management. That breadth allows an eye-care practitioner to fit a wide range of patients within one product family, a practical advantage that can reinforce repeat ordering.
On the CooperSurgical side, Witness automated laboratory tracking is an important product example. Q2 capital equipment demand was strong in the United States and globally, and management said equipment placements create follow-on consumable demand. This equipment-to-consumables model gives CooperSurgical a way to turn a discrete capital sale into a longer customer relationship.
COO's strongest competitive asset is the combination of product breadth, regulatory approvals and practitioner distribution. CooperVision spans spherical, toric, multifocal and toric multifocal lenses, while CooperSurgical covers fertility, genomics, equipment, medical devices, contraception and cryostorage. That portfolio gives the company several routes to customer expansion instead of relying on a single product cycle.
The company also has a long record of share gains. Management said CooperVision achieved its 18th consecutive year of market-share gains in 2025 and holds the number-one global position by contact-lens wearers, with roughly one-third of wearers using CooperVision lenses. The 10-K identifies Johnson & Johnson Vision Care, Alcon and Bausch + Lomb as major competitors, so this share record carries weight in a concentrated global market.
The innovation pipeline targets specific clinical and consumer needs. The next-generation multifocal design is intended to simplify fitting across lighting conditions, distances and patient profiles. Energys combines premium optics with material technology aimed at comfort for digital-device users. MiSight addresses pediatric myopia, while Witness targets laboratory workflow and traceability. COO also protects products through patents, trademarks, trade secrets, licenses and technical know-how.
Operational execution improved in Q2. Operating expenses rose only 1.0% year over year, while non-GAAP operating income increased 19.0% and non-GAAP operating margin reached 27.5%, up from 25.0% in the prior-year quarter. CooperSurgical operating expenses declined for the second consecutive quarter, reflecting the benefits of the prior reorganization and back-office consolidation.
The supply chain is also being actively reshaped. An AI-enhanced inventory-control system is allowing COO to reduce inventory levels, although lower CooperVision production during the process pressures gross margin. Management expects Q3 gross margin of approximately 66.0%, compared with Q2 gross margin of 68.1%, because of foreign exchange, tariffs, freight and lower production.
Tariffs are included at approximately $22M in fiscal 2026 guidance. Management said potential tariff refunds could reach $15M, which creates a defined upside item rather than a vague macro hope. The company also reaffirmed an objective of more than $2.2B of free cash flow from fiscal 2026 through fiscal 2028, including expected litigation payouts. Q2 free cash flow was $96.4M.
The strategic review of CooperSurgical is an additional operational and capital-allocation variable. Management has received indications of interest for the entire business and for individual pieces after reaching settlements covering more than 95.0% of recall claimants. A transaction is not part of the base earnings forecast, but the review gives the board a path to test whether the private-market value of CooperSurgical exceeds the value assigned to it within the public company.
The contact-lens market is moving toward premium daily disposables and silicone hydrogel materials. NIQ reported global contact-lens sales growth of 5.5% by value in 2024 and 4.1% in 2025. Daily disposable lenses reached 61.0% of global value in 2025, up from 57.0% in 2022. That mix shift directly supports MyDay, clariti and other daily silicone hydrogel products.
EMEA provides a useful market reference. EuromContact reported 6.0% growth in the EMEA soft contact-lens market in 2025, with daily disposable lenses up 6.2%. COO's EMEA revenue grew 6.0% organically in Q2, while the Americas grew 7.0%. These results show that COO is participating in the healthier parts of the market rather than relying only on broad category growth.
Fertility and women's health have different demand drivers. U.S. births fell to 3.6 million in 2025, while women aged 30 and older accounted for 53.0% of births. For the first time in the United States, more babies were born to women aged 40 and above than to women under 20. Those demographic facts support demand for fertility services and products, even though clinic utilization and reimbursement can vary by region.
Access is also expanding in specific markets. Beginning in January 2026, most large-group health plans in California covering more than 100 employees were required to cover IVF and infertility treatments. That policy change supports broader treatment access in one of the largest U.S. states and gives CooperSurgical a concrete demand tailwind through its fertility-clinic customer base.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
CooperVision sells through distributors, independent eye-care practices, corporate retailers, authorized resellers and other professional channels. The product is selected through a fitting decision made by an eye-care professional, then replenished by the wearer. This structure gives practitioner relationships and fitting breadth economic importance, particularly for toric, multifocal and specialty lenses.
CooperSurgical serves fertility clinics, hospitals, OB/GYN offices, surgery centers and laboratory customers. Q2 growth was supported by new clinic wins and expansion within existing accounts. Capital equipment sales, including Witness, can deepen those relationships because the installed system supports future consumable purchases and workflow integration.
The customer base also creates purchasing-power risk. COO's 10-K identifies group purchasing organizations and consolidation among medical offices and fertility clinics as competitive factors. Larger buyers can negotiate price, standardize products and demand service commitments. COO's response is portfolio breadth, global availability and products with clinical or workflow differentiation, rather than a strategy based solely on low price.
CooperVision competes against Johnson & Johnson Vision Care, Alcon and Bausch + Lomb, along with smaller companies with narrower product offerings. COO is smaller than the largest diversified eye-care groups, but management describes CooperVision as number one globally by wearers and the company held the number-two position by revenue in the cited fiscal 2024 industry comparison.
The competitive advantage is strongest in premium daily lenses, specialty prescriptions and myopia management. MyDay grew at a double-digit rate in Q2, MiSight revenue grew 24.0%, and toric and multifocal revenue grew 7.0% organically. Those figures show where COO is winning: complex or premium categories where product performance and practitioner confidence carry more weight than basic unit pricing.
CooperSurgical operates in a more fragmented fertility and women's-health market. The company competes on technology, product quality, availability, price and customer service. Its breadth across IVF, genomics, equipment, consumables, OB/GYN devices and contraception gives it cross-selling potential, but fragmented markets can still produce aggressive procurement and price competition.
Foreign exchange is a direct earnings variable for COO. The CFO said favorable currency helped first-half EPS, while foreign exchange is expected to turn negative in the second half of fiscal 2026. The company also cites inflation, tariffs, trade barriers, regulatory developments and supply-chain disruption as risks in its 10-K.
Asia Pacific is the clearest regional headwind. CooperVision revenue fell 6.0% in Q2, with Japan and China weaker than management had anticipated. Legacy hydrogel rationalization will continue to pressure results through part of 2027, although management said the affected product volumes are becoming smaller and the business should return to roughly market growth in the fourth quarter.
Geopolitical events can also affect channel timing. CooperSurgical reported late-quarter distributor restocking in the Middle East after airspace reopened. That event helped Q2 fertility results, but it also demonstrates how regional disruptions can shift revenue between quarters rather than create a permanent change in demand.
Regulatory exposure is material because COO sells approved medical devices and fertility products. The December 2023 embryo-culture-media recall produced a $271.6M net Q2 charge, consisting of a $324.1M settlement accrual partly offset by $52.5M of insurance recoveries. The settlement progress reduces one major overhang, but the event illustrates why product quality, post-market surveillance and regulatory compliance belong in the valuation.
Roughly $2.5B of debt against $110.6M of fiscal 2025 cash leaves Cooper with leverage that is manageable but worth watching as earnings recover.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 revenue rose 8% to $1.08B and non-GAAP EPS climbed 26% to $1.21, showing solid operating momentum despite a $271.6M litigation charge.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reaffirmed fiscal 2026 non-GAAP EPS guidance of $4.58 to $4.66, signaling confidence in continued earnings growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $70.64, COO trades at 14.1x forward earnings and a 0.7 PEG, which looks more attractive than its 58.6x trailing P/E distorted by one-time charges.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report's fair value sits at $82, above the current $70.64 share price and below the next upside thresholds implied by the analyst range.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →COO is a quality medical-device platform with two different but complementary growth engines. CooperVision holds global scale, has delivered 18 consecutive years of share gains and is benefiting from daily silicone hydrogel, multifocal and myopia-management adoption. CooperSurgical delivered 10.0% organic fertility growth in Q2, while its equipment and consumables model supports deeper clinic relationships.
The financial picture is improving beneath a noisy GAAP headline. Q2 non-GAAP EPS rose 26.0%, operating expenses increased only 1.0%, debt declined to $2.46B and management maintained fiscal 2026 EPS guidance. The risks remain concrete: debt is high relative to cash, Asia Pacific is weak, tariffs are pressuring costs and the recall produced a large charge.
A Buy rating is appropriate at the referenced $70.64 price because the forward valuation, earnings estimates and product momentum compensate for those risks. The $82.00 fair value estimate provides the central medium-term anchor. Investors who demand a larger margin of safety should use the $68.00 Buy level or lower, while prices approaching $95.00 require a stronger earnings or strategic catalyst than the current evidence provides.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Cooper Companies posted strong Q2 growth, with earnings and free cash flow improving despite a litigation charge. CooperVision remains the steady core, while CooperSurgical adds strategic upside after major recall claims were largely resolved.
The Cooper Companies, Inc. (COO) rises after posting a strong quarterly beat and lifting full-year earnings guidance. Investors responded to solid contact lens demand, improved profitability, and heavier trading volume, signaling renewed confidence in the healthcare stock’s outlook.
Casey's General Stores, Inc. (CASY) falls in extended-hours trading even after posting a strong Q1 FY2027 earnings beat. Investors focused on mixed operating trends, including softer fuel volumes and a premium valuation, prompting a sharp pullback despite better-than-expected EPS and revenue.